Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Meningococcal Disease

Drug Information

Target Indication

Meningococcal Disease

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Influenza

Heart Transplantation

Non-alcoholic Fatty Liver Disease (NAFLD)

Meningococcal Meningitis

Axial Spondyloarthritis